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FRESH VENOUS 
ALLOGRAFTS IN 
PERIPHERAL ARTERIAL 
RECONSTRUCTION IN DOGS 
Effects o f  
h i s tocompat ib i l i ty  and  
o f  shor t - te rm 
immunosuppress ion  w i th  
cyc lospor ine  A and  
mycopheno la te  mofet i l  
To date, no arterial substitute has been shown to be as effective as the 
autologous aphenous vein in peripheral revascularization procedures. In 
the present study, the venous allograft was evaluated as a vascular 
substitute in terms of patency and induction of host immune reactivity, 
whether used in major histocompatibility complex-incompatible, major 
histocompatibility complex-compatible, or immunosuppressed major his- 
tocompatibility complexlincompatible dogs. The immunosuppressive drug 
therapies were given for a period of 31 days, beginning 1 day before 
transplantation, and consisted of the use of cyclosporine A, mycophenolate 
mofetil, or a combination of both. All histoincompatible allografts were 
thrombosed at 4 or 8 weeks after transplantation with antibody develop- 
ment and cell-mediated cytotoxicity in the graft, whereas histocompatible 
allografts showed late stenosis without immunologic reactions directed 
toward donor cells. Given alone, neither cyelosporine A nor mycophenolate 
mofetii improved the overall patency of venous allografts; thrombosis 
occurred shortly after cessation of immunosuppression. Still, the cyclospo- 
rine A-mycophenolate mofetil combination therapy led to a 100% patency 
rate at 20 weeks after implantation and immune reactions were markedly 
reduced. This study shows that the fresh vein allograft is still an attractive 
and functional alternative to the autologous saphenous vein if the host 
immunologic reactions are controlled by cyclosporine A-mycophenolate 
mofetil immunosuppression. (J THORAC CARDIOVASC SURG 1995;110:1732-44) 
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T he autologous aphenous vein and the internal mammary artery are the preferred blood con- 
duits for coronary a' 2 and peripheral 3 arterial recon- 
struction. However, they can be absent or unsuitable 
in as many as 20% to 30% of patients. Alternative 
blood conduits, such as the expanded polytetra- 
fluoroethylene prosthesis and the chemically pro- 
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cessed human umbilical vein graft (bioprosthesis), 
fail as small-caliber arterial substitutes. Indeed, they 
exhibit poor long-term patency rates 4 because of 
thrombosis and susceptibility to bacterial coloniza- 
tion and lipid uptake. 5 Only viable biologic tissue 
resists infection and lipid retention. 6 Venous al- 
lografts were used in the past and have yielded 
interesting short-term results, 7'8 but were later 
shown to be targets of immune reactions, potentially 
leading to allograft failure. 9 
Since the venous allograft tissue was shown to 
be antigenic, 1° donor-recipient histocompatibility 
matching 11-13 and immunosuppressive th rapies 13-~6 
have been investigated. Furthermore, cryopreserva- 
tion has also been proposed as a way to reduce 
antigenicity and to create a bank of readily avail- 
able tissues. 17-a9 However, conflicting results have 
emerged from these studies so that skepticism re- 
mains about the usefulness of venous allografts 
in small-diameter revascularization procedures. 
To determine the factors that could influence 
venous allograft success, the roles of histocompat- 
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ibility and short - term immunosuppress ive treat- 
ment were evaluated in a canine femoral  artery 
rep lacement  model.  Cyclosporine A (CsA), a po- 
tent inhibitor of  early T-cell activation, and my_ 
cophenolate mofeti l  (MMF),  a new, powerful  
inhibitor of  late T-cell and B-cell activation, were 
used either alone or in combinat ion.  Autografts  
and allografts were implanted and moni tored 
in terms of patency, induct ion of  th rombohema-  
tologic parameter  modif ications, cellular and 
humoral  immune reactions, histologic changes, 
and appearance on scanning electron microscopy 
(SEM). 
Material and methods 
Dog selectien and operation. Twenty-one young adult 
mongrel dogs (4 male and 17 female dogs) and seven 
Labrador etriever littermates (five male and two female 
dogs) approximately 1 year old and weighing 18 to 26 kg 
were selected for the present study. They were treated 
according to the guidelines of the Canadian Council on 
Animal Care. The animals were paired before vascular 
operation, depending on mutual major histocompatibility 
complex (MHC) compatibility as measured by a mixed 
leukocyte culture assay as previously described. 2° Because 
allele-specific typing sera were unavailable, the mixed 
leukocyte culture assay is a good and recognized indicator 
of mononuclear cell reactivity. 21 Dogs were fasted for 12 
hours before the operation. They were anesthetized intra- 
venously with 20 mg/kg sodium pentobarbital (Somnotol) 
and the lungs were mechanically ventilated. They received 
additional halothane (Fluothane) when further anesthesia 
was required. After groin disinfection and exploration, 
each dog received 10 cm long femoral vein segments as 
substitutes for both femoral arteries: an allograft was 
interposed in the right femoral artery, and an autograft 
was used as a control in the left femoral artery. To avoid 
prolonged ischemia, the grafting procedure was done 
immediately after vein excision from the donor with an 
end-to-end anastomotic technique. For the performance 
of open biopsies after operation, to thus avoid stretching 
of the graft, grafts were slightly looped. After operation, 
the dogs were returned to their cages and fed an unre- 
stricted standard iet. 
Experimental groups. The control group consisted of 
nine mongrel dogs and one Labrador, all paired as 
histoincompatible (MHC incompatible). These dogs re- 
ceived a fresh venous autograft and an allograft without 
any treatment. The second group consisted of six un- 
treated Labrador littermates paired as histocompatible 
(MHC compatible). The third group consisted of four 
histoincompatible graft recipients that were given an olive 
oil solution of CsA orally at a dosage of 10 mg/kg per day 
for 31 days, beginning the day before transplantation. The 
fourth group comprised four histoincompatible dogs that 
received MMF in gelatin capsules orally at a dosage of 20 
mg/kg per day, also for a total of 31 days beginning 1 day 
before implantation. Finally, the fifth group was com- 
posed of four histoincompatible dogs that received both 
CsA and MMF in the same dosages previously described 
and for the same period. 
Thrombohematologic testing and follow-up. Changes 
in blood coagulation parameters were measured for each 
dog before transplantation, at the time of the first biopsy, 
and when the dogs were killed. Serum and heparinized 
blood samples were collected periodically after operation 
for donor-specific antibody screening and graft-infiltrating 
lymphocyte culture, respectively. Hematocrit concentra- 
tion was determined by a capillary method, leukocyte and 
platelet counts were done by hematometry, and clotting 
time was done by hemochronometry. In addition, platelet 
aggregation was evaluated by aggregometry, and hemo- 
stasis was assessed by thromboelastography. To assess 
blood susceptibility to clot formation, the thrombogenic 
index (TI) was calculated as TI = Emx/k, where Emx is 
the clot elasticity factor as obtained by the conversion of 
Am (clot stiffness, millimeters) according to a throm- 
boelastograph conversion table provided by the company 
(Hellige, Freiburg, Germany) and k is the start of clot 
formation (minutes). 
Graft patency was determined at periodic intervals by 
Doppler ultrasonographic evaluation. The dogs were 
killed 5 months after transplantation rwhen an allograft 
showed no indication of blood flow. 
Vascular endothelial cell culture. To measure host 
immune reactions directed toward the allograft, asegment 
of jugular vein was excised from each dog the same day 
the transplantation procedure took place, and vascular 
endothelial cells (ECs) were isolated according to the 
method of Jaffe and associates. 22They were cultured in
medium 199 supplemented with heat-inactivated fetal 
bovine serum, EC growth supplement, heparin, fresh 
glutamine, and antibiotics, as previously described, is Cul- 
tures had to reach the third passage before the cells could 
be used. 
Donor-specific antibody screening and cytotoxicity test- 
ing. The development of posttransplant antibodies was 
measured by indirect immunofiuorescence with use of a 
flow-cytometric assay as previously described. 2° Vascular 
graft recipients were screened for antibody formation with 
serum samples collected at 0, 2, 4 or 5, 8, 12, 16, and 20 
weeks after operation. Sera were tested against donor, 
recipient, and third-party ECs and splenocytes (obtained 
at the animal's death). A reaction was considered positive 
when a serum exhibited a shift of at least 10 mean 
fluorescence channels compared with findings in the con- 
trol serum (pooled normal dog serum). 
The cytotoxic activity of flow-cytometric reactive sera 
was assessed by a cytotoxic flow-cytometric assay. In brief, 
ECs were incubated with the corresponding serum and 
washed thoroughly. They were then incubated with rabbit 
complement o which propidium iodide was added, 
washed thoroughly, and fixed in paraformaldehyde before 
being analyzed on a flow cytometer (FACSort, Becton 
Dickinson, San Diego, Calif.). A positive cytotoxic reac- 
tion was observed when a shift of at least 10 mean red 
fluorescence channels was measured for a given serum, 
compared with findings in the control serum. 
Cellular immune reactivity. Graft-infiltrating alloreac- 
tive lymphocytes were cultured from samples obtained by 
open autograft and allograft biopsies done at 2 and 4 
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Table I. Graft patency in littermates, unrelated dogs, and immunosuppressed dogs 
Patency rate (No. of patent grafts) by time (wk) 
Experimental group* 0 2 4 f" 5? 8 12 16 20 
Histocompatible 
Littermates 
Autografts 6/6 6/6 
Allografts 6/6 4/6 
Histoincornpatible 
Untreated 
Autografts 10/10 10/10 
Allografts 10/10 7/10 
CsA 
Autografts 4/4 4/4 
Allografts 4/4 4/4 
MMF 
Autografts:~ 4/4 4/4 
Allografts 4/4 4/4 
CsA + MMF 
Autografts 4/4 4/4 
Allografts 4/4 4/4 
6/6 6/6 6/6 5/6 4/6 
4/6 4/6 4/6 2/6 1/6 
9/10 9/10 9/10 9/10 9/10 
3/10 1/10 0/10 
2/4 2/4 2/4 
2/4 1/4 0/4 
2/3 2/3 
1/4 0/4 
3/4 3/4 3/4 3/4 3/4 
4/4 4/4 4/4 4/4 4/4 
*Experimental groups were as follows: Littermates, untreated histocompatible litt rmates; Untreated, untreated histoincompatible dogs; CsA, CsA-treated 
histoincompatible dogs; MMF, MMF-treated histoincompatible dogs; CsA + MMF, histoincompatible dogs treated with CsA and MMF. 
tGraft patency was assessed at 4 weeks in untreated dogs and at 5 weeks in imrnunosuppressed dogs at performance of the first biopsy. 
~:Only three of the four a tografts could be evaluated for graft patency because ofsevere infection and necrosis none dog's leg observed at 5 weeks. 
weeks for dogs without immunosuppressive th rapy and 
at 5 weeks for those receiving drug therapies. This 
procedure was also done when the dogs were killed. 
The biopsy technique was as follows. After graft explo- 
ration, a 1 cm medial vein graft segment was excised 
and the graft was reclosed by end-to-end anastomoses. 
Lymphocytes were cultured according to the method of 
Dal Col and associates. 23In brief, biopsy sample frag- 
ments were divided into 10 to 15 pieces and cultured in 
a 96-well, round-bottomed microtiter plate in RPMI 
1640 medium supplemented with 10% heat-inactivated 
pooled dog serum, fresh glutamine, antibiotics, 50 U/ml 
interleukin-2, and 105 irradiated (3000 rads) autologous 
feeder mononuclear cells. The medium was changed 
periodically, with the addition of feeder cells once a 
week until sufficient growth was noted (usually 4 
weeks). Cultured lymphocytes were then tested for 
cytotoxic activity against donor, recipient, and third- 
party ECs in a 4-hour 51Cr release assay. Target cells 
(106) were labeled with 100 /xCi of Naz51CrO4 for 90 
minutes at 37 ° C. Then they were incubated with cul- 
tured graft-infiltrating lymphocytes at effector/target 
ratios of 10:1 and 40:1 in a total of 200 txl of culture 
medium devoid of interleukin-2 in a 96-well, round- 
bottomed plate. After a 4-hour incubation, 100 pJ of 
supernatant was removed and counted on a gamma 
counter. Spontaneous 51Cr release was determined by 
incubating target cells alone, whereas maximal release 
was determined by treating the labeled target cells with 
10% Triton X-100 polyoxyethylene (Union Carbide 
Corp., Danbury, Conn.). The percentage of specific EC 
lysis was calculated as follows: 
Specific 51Cr release = 
Experimental release Spontaneous release 
(cpm) (cpm) 
× 100 
Maximal release Spontaneous release 
(cpm) (cpm) 
Graft processing and analysis. A fragment of a biopsy 
specimen and representative anastomotic and midportions 
of explanted grafts (obtained at death) were fixed in 10% 
formalin and later processed for light microscopy and SEM. 
Paraffin sections 5 /~m thick were stained with Weigert's 
stain to reveal elastic fibers and Masson's trichrome stain to 
differentiate fibrin from collagen. Specimens for SEM eval- 
uation were postfixed in carboxyhydrazide and osmium 
tetroxide. Dehydration was obtained by immersion of the 
specimens in a series of ethanol solutions, culminating in 
pure ethanol, followed by critical-point drying with liquid 
CO2 used as the transfer medium. They were then coated 
with a gold-plated alloy before observation under a Jeol 
JSM35 SEM (Soquelec, Montreal, Quebec, Canada) at a 15 
kV accelerating voltage. 
Results 
Graft patency. Dogs in each exper imental  group 
were evaluated periodical ly by Dopp ler  ultrasonog- 
raphy for graft patency. The results are shown in 
Table I. Surprisingly, the autografts in each group 
exhibited different patency rates. In the group of  
untreated histoincompatible dogs, only one au- 
tograft thrombosed,  which was attr ibuted to a tech- 
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nical failure. Two of six autografts were stenosed at 
the end of the protocol (20 weeks) in the group of 
histocompatible littermates. Two autografts oc- 
cluded early after implantation among the four dogs 
treated with CsA, one of three failed in dogs treated 
with MMF, and three of four remained patent at 20 
weeks in dogs receiving a combined immunosup- 
pressive therapy (CsA and MMF). 
In the untreated histoincompatible group of dogs, 
four allografts underwent thrombosis at 4 weeks and 
two thrombosed at 8 weeks. Three dogs had a 
thrombosed allograft at 2 weeks and one had a 
stenosed allograft at 12 weeks. Two early thrombo- 
ses at 2 weeks and three stenoses (two at 16 weeks 
and one at 120 weeks) occurred in the group with 
histocompatible allografts (littermates). Only one 
allograft remained patent for the 20-week implan- 
tation schedule. Allografts implanted in CsA- 
treated dogs thrombosed at 5 (in two dogs), 7, and 
11 weeks, respectively. Treatment with MMF was 
also unsuccessful, with three thrombosed allografts 
at 5 weeks and one at 8 weeks. However, in the 
group of dogs treated with the combined immuno- 
suppressive treatment composed of both CsA and 
MMF, all four allografts were patent at 20 weeks 
after implantation. Three of the explanted grafts 
exhibited a nonocclusive thin mural thrombus in the 
midportion, whereas the remaining allograft showed 
a thrombus-free luminal surface. 
Thrombohematologie parameters. The three un- 
treated histoincompatible dogs, which underwent 
allograft thrombosis at 2 weeks after transplanta- 
tion, showed high TI values at operation (data not 
shown). However, the TI was found to be homoge- 
neous among allother dogs before implantation and 
was shown to increase when thrombosis occurred. 
All other hematologic parameters did not differ 
from one blood collection to another. In the group 
of untreated histocompatible littermates, the hema- 
tologic parameters were not altered by the grafting 
procedure. One of the MHC compatible dogs had a 
high TI at operation and underwent allograft hrom- 
bosis at 2 weeks. Finally, within the immunosup- 
pressed dog groups, no differences in hematologic 
parameters were noted except a reduction of about 
50% of the circulating white blood cell counts in two 
dogs treated with cyclosporine at 5 weeks after 
operation (data not shown). 
Antidonor antibody development. Recipient dogs 
were investigated for antidonor antibody formation 
with the use of donor, recipient, and third-party 
cultured vascular ECs and splenocytes (obtained 
Table II. Posttransplant donor-specific antibodies' 
Posttransplant 
antibody 
development? 
Cytotoxic#y 
Experimental group* Spleen cells ECs on ECs¢ 
Histocompatible 
Littermates (n = 6) 0/6 0/6 NA 
Histocompatible 
Untreated (n = 8) 8/8 8/8 8/8 
CsA (n = 4) 1/4 3/4 2/3 
MMF (n = 4) 3/4 1/1§ 0/1§ 
CsA + MMF (n = 4) 1/4 1/2§ 0/1§ 
NA, Not applicable. 
*Experimental groups were as follows: Littermates, untreated histocompat- 
ible littermates; Untreated, untreated histoincompatible dogs; CsA, CsA- 
treated dogs; MMF, MMF-treated dogs; CsA + MM~ dogs treated with 
CsA and MMF. 
?Posttransplant antibody development was measured with the use of donor 
splenocytes and cultured vascular ECs in a flow-cytometric assay. 
:~The cytotoxic activity of posttransplant antibodies was evaluated by a 
fluorescent cytotoxicity assay with donor cultured vascular ECs. 
§Vascular ECs could not be cultured in three dogs treated with MMF and 
in two dogs treated with CsA and MMF at the time of implantation or at 
the dog's death. 
when the dogs were killed). Cytotoxic activity of 
developed antibodies was also measured against 
donor ECs. As shown in Table II, posttransplant 
antibodies developed in all untreated histoincom- 
patible dogs that reacted specifically against both 
donor splenocytes and ECs but not against autolo- 
gous or third-party cells. These antibodies appeared 
at 4 weeks after implantation i  seven dogs and at 2 
weeks in one, and remained in the recipient serum 
until graft occlusion occurred. Two other dogs with 
early allograft thrombosis (2 weeks) did not show 
the development of antibodies. Furthermore, all 
dogs had posttransplant antibodies of the immuno- 
globulin G isotype (data not shown) that were 
cytotoxic to donor ECs (Table I1). In contrast, no 
untreated MHC-compatible littermates had post- 
transplant antibodies despite th  low patency rates. 
Antibodies against donor ECs developed in three 
out of four CsA-treated ogs, only one of which had 
a cross reactivity with donor splenocytes, uggesting 
that in two of three cases antibodies were directed 
against EC-specific antigens. Moreover, two of the 
three dogs in which antibodies developed exhibited 
cytotoxic activity against donor ECs. Unfortunately, 
we could obtain ECs from only one dog in the group 
of recipients treated with MMF. Antibody-mediated 
reactions were noted in this case, but there was no 
cytotoxic activity. Still, three out of four dogs in this 
group formed antibodies against donor spleen cells. 
In addition, only one dog that was immunosup- 
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Table IlL Graft-infiltrating alIoreactive lymphocytes 
Explanted grafts 
Biopsy growth (No. of cultures) 
First Second 
biopsy* biopsy* Death* 
Pos. Neg. Pos. Neg. Pos. Neg. 
Autografts (n = 28)t 3 18 0 8 2 26 
Allografts 
Histocompatible 
Littermates 0 4 0 4 0 6 
(n = 6) 
Histoincompatible 
Untreated 6 0 1 1 9 1 
(n = lo) 
CsA (n = 4) 0 2 0 4 
MMF (n = 4) 0 0 0 3 
CsA + MMF 0 4 0 4 
(n = 4) 
Pos., Positive; Neg., negative. 
*Open biopsies were done at 2 (first biopsy) and 4 (second biopsy) weeks 
after operation. The culture procedure also took place when the dogs were 
killed using a representative midportion specimen of the entire explanted 
graft. In the immunosuppressive drug-treated groups, the first and only 
biopsy was done at 5 weeks after implantation. The results represent the 
number of specimens in each group in which negative or positive (>10 × 
106 cells) lymphocyte growth was observed. 
#Autografts implanted in each experimental group were considered all 
together in this table. 
pressed with both CsA and MMF showed the devel- 
opment of antibodies against donor ECs and spleno- 
cytes, but without cytotoxic activity. Again, we could 
not culture ECs from two dogs in the latter group, 
probably because of an effect of MMF on ECs. 
Graft-infiltrating alloreactive iymphoeytes. To 
assess the role of cell-mediated immune reactions in 
the outcome of venous allografts, graft-infiltrating 
alloreactive lymphocytes were cultured from biopsy 
specimens taken after operation and at the dog's 
death. Results relative to positive culture growth 
from each biopsy specimen a d explant obtained at 
the recipient's death are shown in Table III. Growth 
was observed mostly with biopsy specimens taken 
from untreated histoincompatible dog allografts. 
Indeed, 9 of 10 dogs had specimens at death that 
showed positive lymphocyte growth within 1 month 
of culture. Moreover, all six first biopsy specimens 
and one of two second biopsy specimens howed 
growth of alloreactive lymphocytes, whereas two 
were contaminated (not shown). Cells obtained 
from these cultures demonstrated cytolytic activity 
against donor ECs (Table IV). In some cases, a 
certain level of cytotoxic activity was measured 
against third-party ECs, which suggested that the 
reactivity was directed against a common antigenic 
determinant. Among 21 first biopsy specimens, 
graft-infiltrating lymphocyte growth was seen in 
three autografts, whereas it appeared in 2 of 28 
autograft specimens obtained at death. One of the 
autografts with cell growth thrombosed at 4 weeks, 
but cytotoxic reactivity was observed against he ECs 
of the allograft donor. In the immunosuppressed 
dog groups, no growth was observed. Three first 
biopsy cultures and one culture obtained at death 
could not yield lymphocyte growth because of con- 
tamination in the group of dogs treated with MMF 
(data not shown). Thus the cytotoxic activity of cells 
infiltrating these allografts could not be evaluated. 
Histologic findings. Autografts in all groups gen- 
erally showed similar histologic features regardless 
of the group. Indeed, except for those with early 
failures (7 of 28), autografts howed no important 
morphologic hanges. They exhibited smooth lumi- 
nal surfaces devoid of thrombus, limited intimal 
hyperplasia, nd a low-grade inflammatory eaction, 
regardless of the time of sampling (Fig. 1, A). 
Because no important histologic change was ob- 
served in the majority of autografts, we can suppose 
that the biopsy procedure did not induce events such 
as thrombosis or intimal hyperplasia by itself. Still, 
allografts demonstrated a different pattern of mor- 
phologic changes. As soon as 2 weeks after opera- 
tion, untreated histoincompatible allografts howed 
intimal destruction with deposition of fibrin on the 
luminal surface. Lymphocytic infiltration was fre- 
quently noted within the intima and the adventitia of 
the graft (Fig. 1, B). At 4 or 8 weeks, or both times, 
thrombus deposition onto the luminal surface was 
observed with decreased lymphocytic infiltration, 
located mainly in the adventitia (Fig. 1, C). Intimal 
thickening was absent in most cases but limited in a 
small proportion of allografts biopsied or explanted 
at the time the dogs were killed. 
Allografts in the group of untreated histocompat- 
ible littermates either thrombosed soon after oper- 
ation or had stenosed by the time the dogs were 
killed (5 months), except in one case in which 
patency was seen. In the latter case, histologic 
findings were comparable to those of autografts 
(Fig. 2, A). However, in the two stenosed allografts, 
no particular histologic hange was noted at 2 weeks 
after transplantation, but important intimal hyper- 
plasia was observed at the time of retrieval (Fig. 2, 
B). Furthermore, the elastic network and vein struc- 
ture were disorganized in these grafts. In the groups 
of dogs treated either with CsA or MMF, histologic 
findings were comparable. Indeed, at 5 weeks after 
implantation, thrombus deposition was observed on 
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Table IV. Cytotoxic activity ofgraft-infiltrating lymphocytes in untreated histoincompatible dogs 
Percentage of specific EC Iysis? 
Donor Third party 
First Second First Second 
Graft recipients* biopsy biopsy Explant biopsy biopsy Explant 
Autografts (n = 2/3) 
283 24.3 
50 20.1 
Allografts (n = 6/9) 
283 52.3 
284 16 
40 9.5 
49 ND 
50 12.5 
285 25.9 
5.1 0 0 
0 0 0 
71.3 13.5 0 
71.7 0 12.5 
3.9 31.8 0 0 15.9 
18.1 ND 0 
0 0 4.6 
20.3 16.8 12.6 
ND, Not done because of culture contamination. 
*Displayed are the graft recipients for which a positive lymphocyte-infiltrating growth was observed with either biopsy or explant (obtained at death) 
specimens or both. Only data from dogs with positive cellular cytotoxicity are presented. The number identifying each dog is iven at the left o  he table. 
tCytotoxicity of graft-infiltrating cultured lymphocytes was evaluated against donor and third-party ECs and was expressed as the percentage of specific 5lCr 
release as detailed in the Materials and methods section. Displayed results correspond to an effector/target ratio of 40:1. 
the luminal surface of most of the allografts, with 
destruction of the intima in all cases. In addition, 
mild to moderate mononuclear cell infiltration was 
observed in all layers of the vein wall, whereas 
subintimal fibrosis was either absent or limited (Fig. 
2, C). 
At 5 weeks, allografts from dogs treated with CsA 
and MMF showed a moderate inflammatory reac- 
tion within the media (Fig. 3,A) and dispersed areas 
of thin fibrin deposition onto the luminal surface in 
some cases. When the dogs were killed (20 weeks), 
these allografts howed a well-preserved vein struc- 
ture. No mononuclear cell infiltration was observed, 
and a thin layer of fibrin or reorganizing thrombus 
(Masson's trichrome-positive stain, not shown) was 
observed on the luminal surface in the midportion 
(Fig. 3, B) but was absent from the anastomotic 
regions (Fig. 3, C). In addition, intimal hyperplasia 
was seen only in the midportions of these allografts 
(Fig. 3, B), and it did not appear to be concentric. 
SEM evaluation. Autografts usually showed 
smooth luminal surfaces covered by endothelium- 
like cells (Fig. 4, A). Nevertheless, ome denuded 
areas were e:~posed to the blood flow, but without 
deposition of any thrombotic material. Untreated 
MHC-incompatible allografts, however, showed 
only limited ,coverage by endothelium-like cells at 
the anastomotic regions (Fig. 4, B), whereas the 
midportions demonstrated complete loss of ECs 
with heavy deposition of thrombotic material (Fig. 
4, C). This pattern of luminal covering by endothe- 
lial-like cells was also similar to that in all throm- 
bosed allografts and autografts in both CsA-treated 
dogs and MMF-treated ogs. In contrast, allografts 
in dogs treated with a combination of CsA and 
MMF showed smooth luminal surfaces after 20 
weeks of implantation. Anastomotic regions were 
partially covered with endothelial-like cells (Fig. 5, 
A), usually without any thrombotic material deposi- 
tion. Interestingly, endothelial-like cells were also 
observed in the midportions of these allografts with 
thin thrombotic material present on subendothelial 
areas (Fig. 5, B). 
Discussion 
The venous allograft represents an interesting 
alternative to the use of the autologous aphenous 
vein or the internal mammary artery in small-caliber 
arterial reconstruction because, in contrast o syn- 
thetic prostheses and bioprostheses, it is resistant to 
lipid uptake and bacterial colonization. 5 However, 
its antigenicity causes host immunologic reactions 
that can lead to graft failure. 24 Donor-recipient 
ABO compatibility was proposed in the past for 
improving the patency of venous allografts, 25 but 
was finally found to have no effect on graft occlu- 
sion. a6 With the objective of improving the patency 
rate of venous allografts and to determine the 
factors involved in graft occlusion, we used a canine 
model for femoral artery replacement. The effect of 
MHC compatibility was evaluated, as well as a 
short-term immunosuppressive tr atment with CsA 
alone, MMF alone, or these two drugs in combina- 
tion. 
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Fig. 1. A, Representative section of autograft explanted at 8 weeks showing normal vein wall structure 
(Weigert's tain, original magnification x 12.5). B, Untreated histoincompatible allograft biopsied at 2 
weeks after transplant showing heavy mononuclear cell infiltration (M) w thin intima and media, with fibrin 
(F) deposition onto the luminal surface (original magnification × 25). C, Untreated histoincompatible 
allograft explanted at 4 weeks with heavy thrombus (T) occluding the luminal surface and markedly 
reduced cellular infiltration but destruction of intima and disorganization of wall structure (original 
magnification x 12.5). L, Luminal surface. 
As expected from previous reports, 27 all the al- 
lografts in the group of untreated histoincompatible 
dogs underwent early thrombosis, usually 4 or 8 
weeks after operation. Three of these allografts 
thrombosed at 2 weeks but were originally im- 
planted in dogs with ahigh TI value at implantation. 
Thus the TI could explain why graft occlusion 
occurred so early without signs of immune reactions 
in two of these three dogs. Donor-specific posttrans- 
plant antibodies developed in all histoincompatible 
recipients of vein allografts in the untreated group 
except in two with a thrombosed allograft at 2 
weeks. Those antibodies appeared at 2 weeks in one 
case or 4 weeks in all other cases, remained present 
in the recipient's erum until graft occlusion was 
observed, and had  cytotoxic activity on donor 
cultured vascular ECs (Table 1I). Characterization 
of posttransplant antibodies revealed that they were 
of immunoglobulin G isotype and that their cyto- 
toxic activity was directed against antigens present 
on both donor splenocytes and ECs, presumably 
MHC antigens, z°Lymphocytotoxic antibodies were 
also found in venous allografts implanted in the 
dog zs and miniature swine 13 and correlated with 
allograft failure. In addition, culture of graft-infil- 
trating lymphocytes allowed us to uncover the in- 
volvement of cytotoxic T cells in the vein allograft 
rejection process. Indeed, a high proportion of 
biopsy and explant allograft specimens in histoin- 
compatible untreated dogs showed positive cell 
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Fig. 2. A, Histologic staining of the only histocompatible allograft that was patent at 20 weeks. 
Endothelium is well preserved, and moderate intimal thickening (I) is present (original magnification × 
12.5). 13, MHC-compatible allograft explanted at 16 weeks because of stenosis. Thrombus (7") is present on 
the luminal surface and important intimal thickening (I) is observed (original magnification x 12.5). C, 
Allograft from a dog treated with CsA explanted at 5 weeks showing moderate cellular infiltration within 
intima and media at 5 weeks and unorganized obstructive thrombus (T) lying on the luminal surface 
(original magnification × 25). L, Luminal surface. 
growth (Table III) and cytolytic activity toward 
donor ECs (Table IV). We suspect hat cells grown 
from allograft specimens were cytotoxic T cells 
because, in some cases tested, no cell-mediated 
cytotoxicity was measured against he K562 cell line 
(sensitive to natural killer cell-mediated lysis), P815 
cell line (resistant o natural killer cell-mediated 
lysis), and HL60 cell line (sensitive to lysis mediated 
by lymphokine-activated killer cells) (data not 
shown). Cell growth was observed in some autograft 
specimens, but cytolytic activity was directed only 
against ECs from the allograft donor. These results 
support the hypothesis according to which cellular 
infiltration is directly involved in the occlusion of 
venous allografts. 29 In kidney 3° and cardiac 31 trans- 
plantation, graft-infiltrating cytotoxic T lymphocytes 
are recognized as good indicators of acute rejection 
phenomena nd show donor-specific lytic reactivity. 
Our results thus correlate with those obtained in 
other transplantation systems. 
Histocompatible allografts from canine litter- 
mates exhibited a poor patency rate at 20 weeks 
after transplantation (1 in 6). In general, MHC 
compatibility only prolonged the patency of venous 
allografts but did not prevent late failure. This 
finding correlates with results reported by Stevens 
and colleagues] 3 who used the miniature swine 
model, and Calhoun and colleagues, 32 who used 
canine littermates. In both studies, MHC-compati- 
ble venous allografts thrombosed later than MHC- 
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Fig. 3. Histologic stainings of allografts from dogs treated with CsA and MMF that remained patent for 
20 weeks after operation. A, Five-week biopsy specimen of a  allograft showing normal wall organization 
and moderate cellular infiltration (original magnification × 25).B, Allograft explanted at 20 weeks showing 
organized thrombus (T) over a nonconcentric area of intimal thickening (I) in midportion (original 
magnification × 12.5). C, Almost unmodified wall structure observed at anastomotic sites of an allograft 
explanted at 20 weeks after operation (distal portion of graft, original magnification × 12.5). L, Luminal 
surface. 
incompatible grafts. However, long-term patency 
was not observed, as in our experiments. In our 
study, factors other than immunologic reactions are 
probably at the origin of graft failure, inasmuch as 
neither antibody development nor graft-infiltrating 
alloreactive lymphocytes could be found in the 
littermates. Another process could also be respon- 
sible for the uncontrolled intimal thickening that led 
to graft stenosis. However, one allograft remained 
patent at 20 weeks without major morphologic 
changes within the wall structure (Fig. 2, A). Thus, 
in certain cases, MHC compatibility could lead to 
results similar to those seen with the use of autolo- 
gous tissues as was proposed in previous tudies. ~2 
To achieve better patency rates, we used immu- 
nosuppressive therapies: CsA, MMF, and a combi- 
nation of these two were assayed in a 1-month 
protocol, beginning the day before operation, thus 
avoiding the long-term side effects seen in pro- 
longed systemic immunosuppression. CsA is a ref- 
erence immunosuppressive agent that is therapeu- 
tically used to prevent solid organ transplant 
rejection. 33 It specifically acts on the helper T cell by 
inhibiting early activation and T cell-mediated func- 
tions. 34 MMF is a semisynthetic derivative of myco- 
phenolic acid, which is a noncompetitive, reversible 
inhibitor of the de novo purine biosynthesis on 
which T and B lymphocytes trictly depend for 
deoxyribonucleic a id replication and thus acts on 
the late stage of activation. 3sBecause MHC-incom- 
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Fig. 4. SEM examination. A, Explanted autograft showing confluent endothelial-like cell lining  
midportion of graft (original magnification × 200). B, Proximal region of a thrombosed untreated 
histoincompatible allograft explanted at 4 weeks with partial colonization by endothelial-like cells and 
exposition of subendothelium to blood flow (original magnification × 200). C, Midportion of an allograft 
denuded of ECs, with deposition of thrombotic material onto the luminal surface (original magnification 
x 200). 
patible venous allografts in our study are the targets 
of both cell-mediated and humoral immune r ac- 
tions, MMF should represent a suitable immuno- 
suppressive agent in preventing immune-medi- 
ated allograft failure. MMF was shown to 
effectively reverse acute renal llograft rejection 36 
and to be as effective as azathioprine in combined 
immunosuppressive therapy in heart transplanta- 
tion. 37 It was also shown to significantly prolong 
dog renal allograft survival at a low dosage of 20 
mg/kg per day. 38 Although this dosage is subopti- 
mal, it was used in the present study, because 
higher dosages induce toxic side effects (gastroin- 
testinal toxicity). 
In our study, CsA treatment at a low dosage of 10 
mg/kg per day for a period of 4 weeks did not 
prevent allograft occlusion beyond 11 weeks. More- 
over, 50% of autografts thrombosed within this 
group of dogs probably because of the formation of 
an angle within the graft in the immediate posttrans- 
plant period. This phenomenon could have ac- 
counted for autograft hrombosis because grafts, 
which were originally looped, failed before the first 
scheduled biopsy procedure. Although it has been 
reported that CsA can improve the patency of 
venous allografts, 16'39'4° other investigators noted 
that short-term cyclosporine therapy did not elimi- 
nate later occlusion. ~3' 29, 41 Interestingly, posttrans- 
plant cytotoxic antibodies, in this group of dogs, 
reacted mostly against donor EC antigens. Because 
reactivity against donor splenocytes was observed in 
only one case without cytotoxic activity, we can 
suppose that MHC antigens were not involved in the 
sensitization of the CsA-treated hosts. Even though 
mild to moderate mononuclear cell infiltration was 
seen in CsA-treated allografts, no alloreactive lym- 
phocytes could be cultured from the grafts. Donor- 
specific antibodies and other mechanisms such as 
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Fig. 5. Scanning electron micrographs (original magnifi- 
cation × 200) of allograft retrieved at 20 weeks from a dog 
that was treated with CsA and MMF. Anastomotic re- 
gions showed almost complete covering of luminal surface 
with endothelial-like c lls without fibrin or thrombotic 
matrix deposition (A), whereas midportion revealed pres- 
ence of endothelial-like cells a ong with thin fibrin (F) 
deposition (B). 
natural killer cell allorecognition 42 could have ac- 
counted for graft failure in this case. 
MMF monotherapy did not produce better re- 
sults. Indeed, none of the allografts was patent at 8 
weeks (Table I). Because graft-infiltrating lympho- 
cytes did not grow (mostly obtained at the dog's 
death), we can postulate that this treatment was 
partially effective, in as much as antibody develop- 
ment was measured against donor splenocytes. Of 
particular interest is that ECs could not be cultured 
in three dogs treated with MMF and in two dogs 
treated with CsA plus MMF. In fact, it has recently 
been reported that MMF can inhibit EC growth in 
vitro. 43 
Despite the poor efficacy of CsA and MMF 
monotherapies, the combined immunosuppressive 
treatment of CsA and MMF yielded a 100% al- 
lograft patency rate at 20 weeks. Antibodies were 
measured in the serum of one out of four dogs, 
reacting with donor splenocytes and ECs but with- 
out cytotoxic reactivity. Furthermore, no graft-infil- 
trating lymphocytes could be cultured from the 
allografts, which suggests a potent effect on the 
immune response. Thin mural thrombotic material 
was observed mainly in the midportion of the ex- 
planted allografts (Fig. 3), demonstrating damage 
toward graft ECs or an effect of MMF, because ECs 
could not be cultured in 50% of these dogs either at 
the time of operation or when they were killed. 
Intimal hyperplasia was not concentric and was 
observed mostly in the midportions of grafts (Fig. 3, 
C); however, it did not lead to graft occlusion as in 
dogs that received an MHC-compatible allograft. 
Thus we can state that treatment with two powerful 
immunosuppressants such as CsA and MMF, acting 
on two different stages of immune cell activation, led 
to alloreactive recognition inactivation and that a 
certain form of immune tolerance to the graft was 
established. The addition of MMF to CsA certainly 
helped in gaining immune tolerance to the allograft 
because CsA alone precludes reaching allograft 
tolerance in dogs. 44 In addition, when used at the 
same dosages as in our experiments, CsA and MMF 
prolong the survival of hepatic allografts in dogs, 45 
demonstrating the efficacy of the combined immu- 
notherapy. A synergistic interaction between the 
two immunosuppressants could be responsible for 
the 100% patency rate observed. However, it would 
have been helpful to measure blood concentrations 
of CsA and MMF to assess this possibility. Never- 
theless, immunosuppression with CsA or MMF 
alone was done with suboptimal dosages. Further 
experiments should be done to establish the optimal 
dosages to use in dogs and then to determine the 
efficacy as compared with CsA-MMF therapy. Still, 
in our venous allograft model, MMF seems to be an 
appropriate immunosuppressant, and it was recently 
shown to prevent intimal thickening in a rat aortic 
allograft model 46 by inhibiting smooth muscle cell 
growth. 45 This characteristic is important in arterial 
reconstruction with the use of venous tissues be- 
cause approximately 50% of peripheral bypass grafts 
fail within 5 years because of intimal hyperplasia. 47
This effect of MMF on intimal hyperplasia could 
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explain the better results obtained with allografts 
from dogs treated with CsA and MMF. 
Although a limited number of dogs was used, this 
study indicates that the use of fresh vein allografts 
with short-term treatment with CsA and MMF in 
combination could lead to long-term acceptance of 
this allogeneic tissue. However, further studies in- 
volving a higher number of allograft recipients and 
longer follow-up periods will be necessary to assess 
the exact role of this immunosuppressive tr atment 
on the outcome of venous allografts used as small- 
diameter arterial substitutes. 
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